We take a look at the key microbiome therapeutics currently in the clinical pipeline for recurrent C. difficile infections and their prospects for the treatment of this disease in the future.
Browsing: Clinical > Clinical Diseases
In our latest infographic we provide a visual snapshot of the infections and immune processes that have been linked with the microbiome thus far, explaining some of the evidence
In this article, the authors test ocellatin peptides against one of the most concerning priority pathogens, Pseudomonas aeruginosa.
In the era of meta-omics, infection control and prevention must consider healthcare-associated infections in the global context of pathobiome.
In this study the authors assess the burden of illness, impacts and costs associated with surgical site infections, concluding that SSIs impart a broad and significant impact on both patients and their families.
As part of our focus around World Antibiotic Awareness Week (13–19 November) we spoke to Professor Jonathan Cooke, a pharmacologist and pharmacist based in the UK who holds a special interest in antimicrobial resistance. He shares his thoughts on this pressing issue below:
For the first time, researchers have employed an electroceutical technique – using electric field-based dressings – to manage biofilm infections. Understanding how this technique could influence host–microbe interactions will be pivotal in its application to wound healing in humans.
Researchers have reported that statins could have an antimicrobial effect against Staphylococcus aureus – indicating that statin users may have a decreased risk of S. aureus bloodstream infections outside of hospitals.
While sepsis is well defined clinically, the molecular immunological mechanisms that underlie the development of sepsis are poorly understood.